cysteamine has been researched along with exenatide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Egido, EM; Hernández, R; Marco, J; Silvestre, RA | 2 |
1 review(s) available for cysteamine and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for cysteamine and exenatide
| Article | Year |
|---|---|
Exendin-4 dose-dependently stimulates somatostatin and insulin secretion in perfused rat pancreas.
Topics: Animals; Arginine; Carbachol; Cysteamine; Dose-Response Relationship, Drug; Exenatide; Glucose; In Vitro Techniques; Insulin; Insulin Secretion; Male; Pancreas; Peptides; Perfusion; Rats; Rats, Wistar; Somatostatin; Somatostatin-Secreting Cells; Venoms | 2004 |
Tungstate stimulates insulin release and inhibits somatostatin output in the perfused rat pancreas.
Topics: Animals; Arginine; Cysteamine; Exenatide; Glucose; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Male; Pancreas; Peptides; Perfusion; Rats; Rats, Wistar; Somatostatin; Tolbutamide; Tungsten Compounds; Venoms | 2005 |